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doi:10.1016/j.ejvs.2010.04.007Abstract Objectives: In recent years ultrasound guided foam sclerotherapy (UGFS) has
become an increasingly popular treatment for varicose veins. Although many published series
detail the results of UGFS, little is known about the factors which are associated with outcomes
and complications. The aim of this study was to identify these factors.
Design: A review of a prospectively collected database of UGFS which commenced in July 2007.
Methods: A successful outcome was defined as complete occlusion of the target vein on
duplex scanning at follow-up. Eight factors were assessed to determine whether they were
associated with outcomes and complications. These factors were age, gender, compliance
with post-procedure compression hosiery, previous varicose vein surgery, single or multiple
sites of injection, concentration of sclerosant, volume of sclerosant and pre-procedure
severity score.
Results: Between July 2007 and July 2009, a total of 126 patients (60 men, 66 women)
attended follow-up visits and had a post-procedure duplex scan. Targets for UGFS
included the great saphenous vein (n Z 75), small saphenous vein (n Z 13) and anterior
accessory great saphenous vein (n Z 8). The remainder of procedures involved other
veins or more than a single target vein. The median timing of follow-up was 3 months
(range 1.5e14 months) with duplex scans revealing complete occlusion of the target vein
in 79% of patients. The only factor associated with a successful outcome was compliance
with post-procedure compression hosiery (p < 0.05). The most frequently encountered
complications following UGFS were skin staining (28%), superficial thrombophlebitis (18%)
and pain (14%). The only factor associated with post-UGFS complications was female
gender (p < 0.05). When complications were analysed in isolation female gender was also
significantly associated with skin staining (p < 0.05), but no other complication.ting 3e6 September, 2009, European Society for Vascular Surgery, Oslo, Norway.
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390 S.C. Thomasset et al.Conclusions: These data suggest that compliance with post-procedure compression hosiery
and gender are important factors associated with a successful outcome and reported
complications following UGFS, respectively.
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reserved.Introduction
Ultrasound guided foam sclerotherapy (UGFS) is a popular
treatment option for varicose veins. A recent survey of
members of The Vascular Society of Great Britain and
Ireland and the Venous Forum of the Royal Society of
Medicine revealed that UGFS was offered to National
Health Service (NHS) patients by 27% of surgeons.1
Orbach is credited as the first to introduce foam scle-
rotherapy to treat varicose veins. In 1950 he described
froth produced by vigorously shaking a syringe containing
air and sclerosant to treat varicose veins.2 However, the
concept of foam sclerotherapy remained relatively
dormant until the mid-1990s, when numerous attempts to
refine the technique were reported.3e5 It was not until 2000
when Tessari described a method of preparing foam using
two disposable syringes and a three-way tap that this
procedure became popular.5
Although a number of studies have reported the results of
UGFS, data on factors associated with outcomes and
complications is relatively sparse. Several studies have sug-
gested that outcome following UGFS is influenced by vein
diameter, with superior outcomes observed when smaller
veins are treated.6,7 In 2007 Myers et al. sought to determine
whether a number of variables were associated with
outcomes following ultrasound-guided sclerotherapy.
Nature of the sclerosant injected (foam vs. liquid), the
dilution and volume of sclerosant, age and vein diameter
were all significantly associated with rates of venous occlu-
sion. Although this study predominantly involved patients
undergoing UGFS, in the first year of the study liquid scle-
rosant was also used.8 In a separate study Myers et al.
describe significant associations between rates of deep vein
thrombosis (DVT) following ultrasound guided sclerotherapy
and vein diameter and the concentration and volume of
sclerosant injected. Liquid sclerosant was also used in the
early phase of this study.9 Morrison et al. have suggested that
the volume of foam injected during UGFS is inversely related
to complications following the procedure. However, average
volumes of foam used in this study were notably high (27 ml
air-based foam, 25ml CO2 based foam).
10 The indications for
UGFS should become clearer as further information on
prognostic factors is elucidated. The aim of this study was
therefore to further define factors associatedwith outcomes
and complications following UGFS.
Methods
A prospectively gathered computerised database of all
patients undergoing UGFS was established in July 2007. In
July 2009 this database was analysed and patients who hadattended follow-up during this two-year period were
included in this study.Indications and technique
All patients presenting with symptomatic varicose veins
CEAP clinical stages 2e6, with truncal vein reflux diagnosed
on duplex ultrasonography were considered suitable for
UGFS. All treated great saphenous and short saphenous
veins had terminal valve incompetence. UGFS was per-
formed by two surgeons, however, one surgeon performed
96% of procedures. Immediately prior to undergoing scle-
rotherapy target veins were marked using a portable duplex
scan (SonoSite Micro Maxx, SonoSite Ltd, Hitchin, UK).
Target veins were cannulated under duplex guidance with
an I/V cannula (18e21 gauge) or butterfly needle (21e25
gauge), depending on the size, depth and tortuosity of the
vein. The great saphenous vein was cannulated immedi-
ately above or just below the knee. As the experience of
the senior author grew the single cannulation technique
evolved into a multiple cannulation technique. Care was
taken to cannulate the varicosities away from perforating
veins. Once cannulated, patients were laid in a supine
position with treated leg elevated.
Foam was generated using the Tessari method,5 mixing
one part sclerosant, sodium tetradecyl sulphate (STS)
0.5e3% (Fibrovein, STD Pharmaceuticals, Hereford, UK)
with four parts air using two syringes and a three-way tap.
Great saphenous veins were treated with 3% STS. Accessory
great saphenous and short saphenous veins were treated
with 1% STS. A concentration of 0.5% STS was reserved for
smaller veins. The average volume of STS injected was
12 ml (range 5e15 ml). Following injection patients were
asked to plantar- and dorsi-flex the ankle to encourage
proximal migration of foam along the target vein and speed
neutralisation of any foam reaching the deep venous
system. Foam pads (STD Pharmaceuticals, Hereford, UK)
were then applied over the treated vein. A class II thigh
length graduated compression stocking with waist exten-
sion (Medi, Hereford, UK) was applied over the foam pads.
Following the procedure foam pads were worn for one week
and stockings were worn for 6 weeks. Outpatient follow-up
appointments were made for all patients following UGFS. At
follow-up a standard questionnaire regarding complications
was completed by a consultant vascular surgeon during
discussion with the patient. Data were collected regarding
superficial thrombophlebitis, pain, skin staining, visual
disturbance, headache, neurological problems, skin ulcer-
ation and any other complications that were encountered.
In addition, the questionnaire included assessment of
Table 2 Variables analysed to determine their relation-
ship with outcome and complications (per procedure).
Categorical variables
Gender
Male 60
Female 66
Previous surgery
No 93
Yes 33
Sites of injection
Single 108
Multiple 18
Maximum concentration of sclerosant (%)
0.5 28
1 12
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and compression stockings for 6 weeks following the
procedure. Patients were also examined at follow-up by
a consultant vascular surgeon and target vein patency was
routinely assessed by duplex ultrasonography of the venous
system.
Analysis
A successful outcome was defined as complete occlusion of
the target vein on duplex analysis at follow-up. Eight vari-
ables were assessed to determine whether they were
associated with outcomes and complications. These vari-
ables were age, gender, compliance with post-procedure
compression hosiery, previous varicose vein surgery, single
or multiple sites of injection, concentration of sclerosant,
volume of sclerosant and pre-procedure Clinical-Etiology-
Anatomy-Pathophysiology (CEAP) severity score. Categor-
ical variables were correlated with outcome and compli-
cations using the chi-squared test. Continuous variables
were compared with outcome and complications using
binary regression analysis. Statistical analysis was per-
formed using the Statistical Package for Social Sciences
13.0 (SPSS, Chicago, IL). A p value of <0.05 was consid-
ered significant.
Results
Between July 2007 and July 2009, 235 patients underwent
UGFS. Of these 116 patients (53 male, 63 female), who
underwent a total of 126 UGFS sessions, attended follow-up
appointments. The median age of patients undergoing foam
sclerotherapy was 55 years (range 18e80 years). Targets for
sclerotherapy included the great saphenous vein (n Z 75),
small saphenous vein (n Z 13) and accessory great saphe-
nous vein (n Z 8). The remainder of procedures involved
other veins or more than a single target vein (n Z 30)
(Table 1). Thirty-three patients had undergone previous
varicose vein surgery. Ten patients underwent UGFS twice
during the study period. Five underwent UGFS to different
legs. Of the remaining patients, 4 had a second session of
UGFS for residual veins in the region of those initially
treated. One patient had a second session of UGFS to veins
in a different distribution of the same leg.
The median timing of follow-up was 3 months (range
1.5e14 months) following treatment. Duplex scans at
follow-up revealed complete occlusion of the target vein
following 79% of procedures (nZ 100). Partial occlusion ofTable 1 Veins treated with UGFS (per procedure).
Great saphenous 75
Small saphenous 13
Anterior accessory great saphenous 8
Great saphenous vein and varices 9
Small saphenous vein and varices 3
Anterior accessory great saphenous
and varices
2
Great saphenous and anterior
accessory great saphenous
3
Other varicosities including unnamed residuals 13the target vein was evident following 14% of procedures
(n Z 18) and a patent target vein was seen after 6% of
procedures (n Z 8). CEAP severity score declined in 123
patients following foam sclerotherapy and remained static
in 3 patients. Complications of UGFS were superficial
thrombophlebitis (nZ 23, 18% of procedures), pain (nZ 18,
14% of procedures), skin staining (n Z 35, 28% of proce-
dures), deep vein thrombosis (DVT) (n Z 1, 1% of proce-
dures), allergic reaction (nZ 1, 1% of procedures) and skin
blistering (nZ 1, 1% of procedures). A total of 48 patients
experienced one, or more, of these complications. No
patients experienced visual disturbance, a headache or
other neurological symptoms.
Eight variables were analysed to determine whether they
were associated with outcome and complications (Table 2).
Of the variables analysed compliance with post-procedure
compression hosiery was the only factor associated with
a successful outcome (p< 0.05). Female gender was the only
factor associated with post-treatment complications
(p < 0.05). When complications were analysed in isolation
female gender was also significantly associated with skin
staining (p < 0.05), but no other complication.
Discussion
Since the new found interest in UGFS in mid 1990s, many
reports have emerged detailing outcomes of the procedure.
A systematic review conducted by Jia et al. based on 69
studies of UGFS concluded a median rate of target vein
occlusion of 87% (range 60e98.2).11 In this series 79% of
target veins were completely occluded on duplex scans at3 86
Pre-procedure CEAP
2 12
3 46
4 58
5 10
Compliance with compression
Yes 118
No 8
Continuous variables
Median age 55 (18e80)
Median volume of sclerosant (ml) 12 (5e15)
CEAP, Clinical-Etiology-Anatomy-Pathophysiology severity score.
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partially occluded. These results therefore compare
favourably with other published series. UGFS is not free of
complications. However, large multicentre studies have
demonstrated a low rate of significant complications.12
Stroke,13 anaphylaxis6 and pulmonary embolism14,15 have
been described, but are extremely rare. In this series 18% of
patients developed superficial thrombophlebitis, which is
higher than reported in the literature. The majority of
these patients were in the early phase of the study when
truncal varicosities of >10 mm were treated. Rates of skin
staining (28%) and pain (14%) compared favourably with the
published literature. One patient developed a DVT (1%),
one patient developed skin blistering (1%) and another had
an allergic reaction (1%). The DVT described in this series
was below-knee and occurred following treatment of the
great saphenous vein and a varix with 15 ml 3% STS. Skin
blistering was experienced by one patient and was related
to the tape applied. This was therefore thought to be due
to tape traction or an allergic reaction.
Concentration of the sclerosant and its effect on outcome
is widely debated in the literature. Most studies have used
1e3% STS or polidocanol to produce foam. A small rando-
mised study, involving twenty patients, has suggested that
sodium tetradecyl sulphate and polidocanol have similar
efficacy, tolerability and patient satisfaction.16 Although
some randomised control studies have reported superior
efficacy with higher concentrations of sclerosant,17 others
have questioned the importance of sclerosant concentra-
tion.18 Ameeting of European experts in 2006, failed to reach
a consensus regarding foam concentration, however, did
suggest that the volume of foam is also important and that
notmore than 10ml of foam produced by Tessari’s technique
they should be injected in a single session.19
Compliancewith post-procedure compressionhosierywas
the only factor associated with a favourable outcome
following UGFS in this study. With the exception of female
gender, this series failed to identify any major factor asso-
ciated with complications following UGFS. Complications in
this study were assessed using a questionnaire and it does
seemprobable that female patients aremore likely to report
cosmetic complications, for example skin staining.
Conclusion
UGFS offers an alternative to surgical treatment for varicose
veins and our clinical series confirms that it is effective and
safe. Compliance with post-procedure compression hosiery is
the singlemost important factor associatedwith a favourable
outcome following ultrasound guided foam sclerotherapy. It is
therefore of absolute importance that patients are given clear
instructions regarding compression hosiery and the impor-
tance of adhering to these is emphasised.
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